Perspective Therapeutics (CATX) Assets (2011 - 2026)
Perspective Therapeutics (CATX) reported Assets of $410.8 million for Q1 2026, up 24.72% on a YoY basis from $329.3 million in Q1 2025, and up 53.86% sequentially from $267.0 million in Q4 2025.
Perspective Therapeutics (CATX) Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 16 years of Assets data on file, last reported at $410.8 million in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 24.72% year-over-year to $410.8 million; the trailing twelve-month figure through Mar 2026 stood at $410.8 million (up 24.72% YoY), and the FY2025 full-year result was $267.0 million, down 21.73% from the prior year.
- Assets improved to $410.8 million in Q1 2026, from $267.0 million in the prior quarter.
- In the past five years, Assets ranged from a high of $410.8 million in Q1 2026 to a low of $58.1 million in Q4 2022.
- A 5-year average of $218.6 million and a median of $267.0 million in 2025 frame the typical range for Assets.
- Across the five-year window, Assets soared 253.93% in 2024 and decreased 24.63% in 2025, its largest moves.
- Tracing CATX's Assets over 5 years: stood at $58.1 million in 2022, then surged by 68.51% to $97.9 million in 2023, then jumped by 248.45% to $341.1 million in 2024, then decreased by 21.73% to $267.0 million in 2025, then jumped by 53.86% to $410.8 million in 2026.
- Business Quant data shows CATX's Assets at $410.8 million in Q1 2026, $267.0 million in Q4 2025, and $294.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 6.63 Bn |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 37.13 Bn |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | 10.46 Bn |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 31.92 Bn |
| 10 | Perspective Therapeutics | 296.01 Mn | 296.01 Mn | - | 410.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 410.77 Mn |
| Dec 31, 2025 | 266.97 Mn |
| Sep 30, 2025 | 294.83 Mn |
| Jun 30, 2025 | 310.73 Mn |
| Mar 31, 2025 | 329.35 Mn |
| Dec 31, 2024 | 341.10 Mn |
| Sep 30, 2024 | 391.15 Mn |
| Jun 30, 2024 | 385.92 Mn |
| Mar 31, 2024 | 278.29 Mn |
| Dec 31, 2023 | 97.89 Mn |
| Sep 30, 2023 | 110.52 Mn |
| Jun 30, 2023 | 120.15 Mn |
| Mar 31, 2023 | 127.65 Mn |
| Dec 31, 2022 | 58.09 Mn |
| Sep 30, 2022 | 62.54 Mn |
| Jun 30, 2022 | 64.44 Mn |
| Mar 31, 2022 | 66.11 Mn |
| Dec 31, 2021 | 67.25 Mn |
| Sep 30, 2021 | 68.71 Mn |
| Jun 30, 2021 | 70.42 Mn |